Veeda Clinical Research Gets Expert Committee Nod To Conduct BA/BE Study Of Ibrutinib For Export
New Delhi: Veeda Clinical Research Limited got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the BA/BE study of the the anti-cancer drug Ibrutinib.
This came after the firm presented the BA/BE study Protocol No. 25-VIN-0162, Version No. 01, Protocol Date 16-APR-2025 for conducting BA/BE study for export purpose only, before the committee.
Ibrutinib is in a class of medications called kinase inhibitors. Ibrutinib is a targeted therapy that works by inhibiting Bruton's tyrosine kinase (BTK), a protein crucial for B-cell receptor signaling. By blocking BTK, ibrutinib disrupts the signaling pathways that promote B-cell survival and proliferation, ultimately leading to the death of cancerous B-cells. This mechanism of action makes ibrutinib effective in treating various B-cell malignancies, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.